Αποτελέσματα Αναζήτησης
Lincy LAL | Cited by 1,157 | of University of Texas Health Science Center at Houston, Texas | Read 165 publications | Contact Lincy LAL
Eltrombopag is a well-studied treatment for primary ITP, but evidence is scarce for sITP. We evaluated real-world use of eltrombopag for sITP using electronic health records. Eligible patients had diagnoses of ITP and a qualifying predisposing condition, and eltrombopag treatment.
11 Σεπ 2020 · The second-line of therapy (LOT2) index date was the date of the first prescription for medication (eltrombopag, rituximab, romiplostim) or splenectomy date, collectively referred to as LOT2 index therapy.
Observational and Clinical Outcomes Researcher, Effective Team Leader · Accomplished Research Director with significant experience in Pharmaceutical and Healthcare clinical research, with over 70...
2 Μαρ 2021 · Lincy S. Lal et al., Evaluation of treatment patterns and outcomes in patients diagnosed with genitourinary (GU) cancers with linked claims plus prior authorization data.. JCO 39 , 284-284 (2021).
21 Ιουν 2023 · Evaluate treatment outcomes in mCRC patients who received first-line (1L) bevacizumab-awwb at treatment initiation or as continuing bevacizumab therapy (switched from RP). A retrospective chart review study.
2 Ιουν 2022 · Lincy S. Lal et al., Comparison of DNA sequencing, immunohistochemistry, and in-situ hybridization techniques to determine HER2 status in metastatic breast cancer patients.. JCO 40 , e13045-e13045 (2022).
